Eleva Reaches Industrial Production Scale and Prepares for Clinical...
Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor HEleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in...
View ArticleEleva Enters Clinical Development of Difficult-To-Express High-Potential...
Eleva Enters Clinical Development of Difficult-To-Express High-Potential ProteinsEleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as...
View ArticleClik here to view.
Eleva Appoints Björn Cochlovius as New CEO
Björn Cochlovius New CEO of ElevaSeasoned Molecular Biologist and Entrepreneur Leads German Biotech Company into its Next DevelopmentBjörn Cochlovius Ph.D. has become the new CEO of Eleva, a...
View ArticleClik here to view.
Eleva Appoints Henrik Luessen as New CBO
Eleva Appoints Henrik Luessen as new Chief Business Officer as Company’s Pipeline Accelerates Toward Key Value Inflection PointsProprietary Fabry disease therapy RPV-001 has completed Phase 1b Study;...
View ArticleClik here to view.
FOUR
Upcoming webinar05 December, 2024 MS-Teams 1PM (CET) Recorded FOUREdition FOUR of our webinar series will zoom in on spectrum 2 and provide more insight into Eleva’s technology. Stay in the...
View ArticleClik here to view.
THREE
Upcoming webinar17 October, 2024 MS-Teams 1PM (CET) Recorded THREEWebinar THREE is dedicated to pediatric case reports and Eleva’s CPV-104 study program. Stay in the loopSubscribeSpeakers To be...
View ArticleClik here to view.
TWO
Upcoming webinar13 June, 2024 MS-Teams 1PM (CET) Recorded TWOWebinar TWO will focus on diagnostics and the disease spectrum of C3 Glomerulopathy, zooming in on spectrum 1. Join to our upcoming webinar...
View ArticleClik here to view.
ONE
Previous webinar14 March, 2024 MS-Teams 1PM (CET) Recorded ONEKicking off the 2024 webinar series, our invited speakers will talk through complement diseases and C3G particularly. Watch our recorded...
View ArticleClik here to view.
ZERO
Previous webinar00.00.2024 Zoom 1PM (CET) Recorded ZEROLorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis...
View ArticleClik here to view.
Eleva Publishes Preclinical Data on Proprietary Factor H Therapy
Eleva Publishes Preclinical Data on Proprietary Factor H Therapy for Complement Disorders as Program Advances Toward Clinical TrialsData demonstrates CPV-104’s therapeutic potential as complement...
View ArticleEleva publishes preclinical data on proprietary Factor H therapy
Eleva publishes preclinical data on proprietary Factor H therapy for Complement Disorders as Program Advances Toward Clinical TrialsData demonstrates the therapeutic potential of Factor H (CPV-104) as...
View ArticleClik here to view.
Webinar One
ONEKicking off the 2024 webinar series, our invited speakers will talk through complement diseases and C3G particularly. Watch our recorded sessionVideoSpeakersDr. Bjoern CochloviusCEO Eleva Eleva...
View ArticleClik here to view.
Webinar Two
TWOWebinar TWO will focus on diagnostics and the disease spectrum of C3 Glomerulopathy, zooming in on the histological spectrum. Join to our upcoming webinar today!register hereSpeakersDr. Andreas...
View ArticleClik here to view.
Webinar Three
THREEWebinar THREE is dedicated to pediatric case reports and Eleva’s CPV-104 study program. Stay in the loopsubscribeSpeakersTo be announcedMore information soon To be announcedMore information soon...
View ArticleClik here to view.
Webinar Four
FOUREdition FOUR of our webinar series will zoom in on spectrum 2 and provide more insight into Eleva’s technology. Stay in the loopsubscribeSpeakersTo be announcedMore information soon To be...
View Article